Natural chalcones have been found to possess a small molecular weight and a lower toxicity profile compared to the other AChE inhibitors, making them a more attractive option for the treatment of Alzheimer’s disease [37]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.